drugset / Trial / NCT03833999

Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea

NCT03833999

Phase 4 Completed 16 enrolled University of Nottingham
RandomizedCrossoverDouble-blindBasic science

Summary

This is a double-blind, two period, two treatment crossover trial of ondansetron verses placebo studying the effects of ondansetron in the small and large bowel, specifically its effects on the amount of water in the gut, measured by MRI.

Timeline

Start
2018-10-16
Primary completion
2019-06-27
Completion
2019-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 8 mg Oral
Background Lactulose Other / unclassified 20 ml